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Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder. The pathogenesis
of this disease is associated with gene and environmental factors. Mutations in
leucine-rich repeat kinase 2 (LRRK2) are the most frequent genetic cause of familial and
sporadic PD. Moreover, posttranslational modifications, including protein acetylation, are
involved in the molecular mechanism of PD. Acetylation of lysine proteins is a dynamic
process that is modulated in PD. In this descriptive study, we characterized the acetylated
proteins and peptides in primary fibroblasts from idiopathic PD (IPD) and genetic PD
harboring G2019S or R1441G LRRK2 mutations. Identified acetylated peptides are
modulated between individuals’ groups. Although acetylated nuclear proteins are the
most represented in cells, they are hypoacetylated in IPD. Results display that the level
of hyperacetylated and hypoacetylated peptides are, respectively, enhanced in genetic
PD and in IPD cells.
Keywords: acetylation, LRRK2, peptides, Parkinson, proteins
INTRODUCTION
Parkinson’s disease (PD) is a disabling neurological disorder that is in progressive evolution. This
neurodegeneration mainly affects the dopaminergic neurons of the susbtancia nigra pars compacta
that are in part responsible for clinical motor symptoms. The widespread of this neurodegeneration
from themidbrain to other neurotransmitter (serotoninergic and noradrenergic) systems elicits the
appearance of non-motor symptoms (Politis and Loane, 2011; Deusser et al., 2015). Although well
not understood, the etiopathogenesis of PD has thought related to environmental factors and gene
mutations. Almost 90% of PD cases are sporadic (Ammal Kaidery et al., 2013), and may due to
the susceptibility of genetic predisposition to environmental factors (Yakhine-Diop et al., 2014).
Mutations in leucine-rich repeat kinase 2 (LRRK2) have been associated with autosomal dominant
PD and involved in familial and idiopathic cases. Among six pathogenic LRRK2 mutations
Abbreviations: CI, Confidence interval; FA, Trifluoroacetic acid; FDR, False decoy recovery; GAPDH, Glyceraldehyde-3-
phosphate dehydrogenase; H2B, Histone 2B; HAT, Histone acetyltransferase; HDAC, Histone deacetylase; ID, Identification;
IPD, Idiopathic Parkinson’s disease; K, Lysine; LC-MS, Liquid chromatography-mass spectrometry; LRRK2, Leucine-
rich repeat kinase 2; PD, Parkinson’s disease; PDHA1, Pyruvate dehydrogenase; PSPEP, Proteomics System Performance
Evaluation Pipeline Software; ROS, Reactive oxygen species.
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(R1441G/C/H, Y1699C, G2019S, and I2020T), the most frequent
is the G2019S that affect almost 5% of familial PD and 2% of
sporadic PD (Li et al., 2014). G2019S and R1441G are located,
respectively, in the kinase and GTP domains of LRRK2 protein.
Both mutations participate in the pathogenicity of PD through
the impairment of LRRK2 enzymatic activity (Martin et al., 2014).
Evidence has reported that PARK genes, among other
synuclein (SNCA) and LRRK2, regulate epigenetic mechanisms,
thereby modulate gene expression (Coppedè, 2012). Indeed, gene
expression is altered through posttranslational modifications
of histones (methylation, phosphorylation, ubiquitination, and
acetylation) and affects individual phenotypes (Ammal Kaidery
et al., 2013). Parkinsonism-related toxins modulate histone
acetylation by either decreasing histone deacetylase (HDAC)
activity (Song et al., 2011) or increasing histone acetyltransferase
(HAT) activity (Song et al., 2010). Studies, in PD post mortem
brains, have reported that histone acetylation is upregulated in
midbrain neurons; however, in some patients, this acetylation
level varies differentially according to the brain regions and cell
types (Park et al., 2016).
Acetylation is the transfer of an acetyl group from acetyl
coenzyme A to the ε-amino group of lysine residues in
proteins (histone and non-histone proteins) or to the α-amino
group of the N-terminus of proteins. N-terminal acetylation
is an irreversible reaction that is catalyzed by N-terminal
acetyltransferases, whereas lysine acetylation is regulated by the
balance of two enzymes HAT and HDAC (Drazic et al., 2016).
The combination of these both acetylation reactions constitutes
the acetylome. Acetylome in PD models is poorly characterized,
only the variation of histone acetylation has been widely reported.
Given that it may have an important role in PD pathogenesis,
we identified some of those proteins that are acetylated in
PD-associated (G2019S and R1441G) LRRK2 mutations and
idiopathic PD. Importantly, there are more acetylated peptides




Fibroblasts from PD patients (with or without LRRK2mutations)
and from control subjects were provided by Dr. Adolfo
López de Munaín. Experiments were performed using four
cell lines: Control (Co, patients who did not develop PD),
IPD (IPD, PD patients without LRRK2 mutations), GS (PD
patients with G2019S LRRK2 mutation), and RG (PD patients
with R1441G LRRK2 mutation). This study was carried out
in accordance with the recommendations of Comité Ético
de Investigación Clínica del Área Sanitaria de Gipuzkoa. All
subjects gave written informed consent in accordance with
the Declaration of Helsinki. Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Sigma-Aldrich, D6546)
supplemented with 10% of fetal bovine serum (FBS, Sigma-
Aldrich, F7524), 1% L-glutamine (Sigma-Aldrich, G7513)
and 2mL streptomycin/penicillin (HyClone, Thermo Fisher
Scientific, SV30010) at 37◦C in 5% CO2/95% air. To confirm the
G2019S or R1441G LRRK2mutations in cells, DNAwas extracted
(Macherey-Nagel Kit, 740952.50) and sequenced at STAB VIDA
(Caparica, Portugal). In this study, we worked with pooled cell
lines ranging from three to four cell lines (Table 1). Human
fibroblasts (HFs) were seeded at a density of 3.5 × 104 cells/mL
and from lower passages.
Digestion and Desalting of Peptides
Samples (Co, IPD, GS, and RG) were resuspended in 400 µL
of 50mM ammoniun bicarbonate and quantified by Bradford
protein assay (BioRad). For each sample, 2mg protein were
diluted in 8M Urea in-solution trypsin digestion. Proteins
were reduced, alkylated, and digested with a 1:20 (w /w) ratio
of recombinant trypsin sequencing grade (Roche) overnight
at 37◦C. Peptides from digested proteins were desalted and
concentrated with a C18 reversed phase chromatography (ZipTip
C18, Millipore) and the peptides were eluted in 50% acetonitrile
(ACN)/0.1% trifluoroacetic acid (FA). Finally, the samples were
freeze-dried in SpeedVac and dissolved in 200 µL of NETN
(100mM NaCl, 1mM EDTA, 50mM Tris pH 8, and 0.5%
Nonidet P40) buffer for affinity enrichment of lysine-acetylated
peptides.
Enrichment of Lysine-Acetylated Peptides
Samples in NETN buffer were incubated with anti-acetyl lysine
agarose beads (catalog no. PTM-104, PTM Biolabs) at 4◦C
overnight with gentle shaking. After incubation, the beads were
carefully washed three times with NETN buffer, twice with ETN
buffer (1mM EDTA, 50mM Tris pH 8, and 100mM NaCl), and
once with water. The immunoprecipitated peptides were eluted
with 1% FA and dried in a SpeedVac. The resulting peptides
were cleaned with C18 Zip Tips (Millipore) according to the
manufacturer’s instructions and were dissolved in 12 µL of 2%
ACN/0.1% FA then subjected to LC–MS/MS analysis by Triple
TOF 5600 (SCIEX).
TABLE 1 | Presentation of the four groups of pooled cell lines.
Groups Names Dates of Birth Genotypes
Co1 LRRK2 WT




IPD IPD2 1928–1954 LRRK2 WT
IPD3 LRRK2 WT
GS1 G2019S Heterozygous
GS GS2 1945–1949 G2019S Heterozygous
GS3 G2019S Heterozygous
RG1 R1441G Heterozygous
RG RG2 1931–1942 R1441G Heterozygous
RG3 R1441G Heterozygous
The control group consists of four individuals, the IPD, GS and RG groups of three
individuals each. We present in this table the range age of each group, and the genotype
of each individual.
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Protein Identification
MS/MS data sets were identified using Mascot licensed version
2.3.02 (Matrix Sciences) and ProteinPilot (revision 4895; AB
SCIEX 5.0.1) using the Paragon algorithm (5.0.1.0, 4874). All
data files were searched using the SwissProtHuman 2015_09_17
database with 42136 sequences. Search parameters in Mascot
for acetylated peptides were as follows: trypsin digestion with
five missed cleavages to account the inability of trypsin to
cleave at acetylated lysine residues. Lysine acetylation, N-
terminal acetylation and methionine oxidation were set as
variable modifications, and carbamidomethyl cysteine as a fixed
modification. Precursor ion and fragment ion mass tolerances
were set to 30 ppm and 0.6 Da, respectively. Further, the decoy
database search (Mascot integrated decoy approach) was used
to false decoy recovery (FDR) calculation and the percolator
algorithm applied to Mascot results. The acceptances criteria
for proteins identification were a FDR < 1% and at least
one peptide identified with a confidence interval (CI > 95%).
In ProteinPilot, the following sample parameters were used:
trypsin digestion, cysteine alkylation with iodoacetamide, and
acetylation emphasis. A thorough identification (ID) search
was done. Thus, a local FDR of 1% was chosen using the
ProteinPilot FDR analysis tool (PSPEP) algorithm and a peptide
CI value of 95%.
Protein Relative Quantification
For human proteins relative quantification in (Co, IPD, GS,
and RG) samples, the Raw profile data files (.raw) were
imported into Progenesis LC-MS for proteomics (64-bit version
v 4.1; Nonlinear Dynamics/Waters). Imported runs were
chromatographic aligned to the reference run identified by the
software. All runs were selected for peak picking with the
automatic sensitivity method (default settings) and filtered to
include only peaks with a charge state between 2 and 5. All
detected features were normalized against the reference run by
Progenesis LC-MS. Between-subject comparison was used as
experimental design (Co, IPD, GS, and RG). Spectral data from
selected features (p-value < 0.05) were transformed to Mascot
generic format (MGF) files with Progenesis LC-MS and exported
for peptide/protein identification to Mascot search engine, using
the searched parameters above described. Mascot search results,
that exceed the acceptance criteria for identification (FDR <
1%, peptides with individual ion scores >13, p < 0.05), were
imported into Progenesis LC-MS as XML files and analyzed
according to the following criteria: only were used quantitation
from non-conflicting peptides. For each protein, the number or
reported peptides was determined by counting unique peptide
sequence. Only proteins reported by one or more peptides with a
p-value< 0.05 were quantified.
Protein abundance was calculated from the sum of all unique
normalized peptide ion abundance. Protein reported abundance
is the geometric mean of the biological replicates. Proteins with
a likelihood of quantification smaller than 0.05 (Anova p-value)
were considered to be significantly regulated. Normalized peptide
intensities were used to calculate fold-changes between samples.
Relative abundance of human proteins (fold change) in three
conditions compared with corresponding proteins in control
samples were quantified by the ratio of summed peptide ion
normalized abundance in each group to evaluate the enrichment
of the protein. Differentially expressed proteins (p < 0.05) were
considered with a fold change ≥1.3 and at least 1 identified
peptides in at least one of replicates.
Immunofluorescence
HFs were seeded on 96-well plate at a density of 3500
cells/well. Cells were successively fixed with 4% PFA and
permeabilized with 0.1% Triton (Sigma-Aldrich, T9284) for
20 and 5min, respectively, at room temperature (RT). Once
permeabilized, plated cells were incubated with bovine serum
albumin (BSA)/PBS solution (1 mg/mL) for 1 h at RT and
then with the primary antibody acetyl-H4 (G-2) (Ser1K5K8K12)
(1:50, Santa Cruz Biotechnology, sc-393472), while shaking
overnight at 4◦C. The following day, cells were reincubated
with Alexa Fluor R© 568 (1:100 Thermo Scientific, A11004)-
conjugated secondary antibodies for 1 h at RT. Nuclei were
stained with Hoechst 33342 (2µM, Sigma Aldrich, B2261).
Images were visualized using an Olympus IX51 inverted
microscope.
Statistical Analyses
Statistical analyses were assessed by Student’s t-test, Chi-Squared
test or Anova test. The results were considered significant at
p<0.05.
RESULTS
Detection of Acetylated Proteins
We determined the N-terminal acetylation and acetylated lysine
(Ac-K) proteins in fibroblasts from PD patients and control
subjects. In Tables 2, 3, we have listed some of those acetylated
proteins. Some of them (fructose bisphosphate aldolase
C (ALDOC), Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), Alpha-Enolase, pyruvate kinase) are enzymes that
participate at different steps of glycolysis pathway (TeSlaa and
Teitell, 2014). The rest of acetylated proteins are implicated
in cell proliferation, acetylation, apoptosis and nucleosome
wrap, as well in the link between glycolysis and citric acid
cycle. Most of those proteins were located in the nucleus
and the cytoplasm and represent, respectively, 52 and 36%
of acetylated proteins in PD patients (Figure 1A). The less
represented were found in plasma membrane (8%) and
mitochondrion (4%).This distribution did not change in the
control group but the proportion slightly differs. The number
of Ac-K sites on proteins varied from one to ten (Tables 2, 3)
and can be found on distinct peptides. Furthermore, in PD
models some acetylated proteins had more or less Ac-K
sites than Control line (Table 2). Interestingly, we found
that the ratio of acetylated peptides/non-acetylated peptides
was enhanced in GS and RG cells while it was decreased
in IPD cells (Figure 1B). We inferred that there were more
acetylated peptides levels in familial PD than in sporadic
PD. These variations were significant between genetic and
idiopathic PD.
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TABLE 2 | Acetylated proteins in fibroblasts from PD patients with or without
LRRK2 mutation.
Protein ID Protein Name Subcellular Location Ac-K Sites
P07355 Annexin A2 Extracellular space, Extracellular
matrix
10
P04083 Annexin A1 Nucleus, Cytoplasm, Cell
membrane
1
P08670 Vimentin Cytoplasm 2
Q9BQE3 α-Tubulin 1C Cytoplasm, Cytoskeleton 1
P68363 α-Tubulin 1B Cytoplasm, Cytoskeleton 1
P14618 Pyruvate kinase Cytoplasm, Nucleus 2
Q6PEY2 α-Tubulin 3E Cytoplasm, Cytoskeleton. 1
P08758 Annexin A5 – 4
P21333 Filamin-A Cytoplasm, Cell cortex,
Cytoskeleton.
1
P62805 Histone H4 Nucleus, Chromosome 4
Q9GZZ1 NAA50 Cytoplasm 2
Q09472 HAT p300 Cytoplasm, Nucleus. 5
Q92793 CBP Cytoplasm, Nucleus. 2
Q99880 H2B1L Nucleus, Chromosome 4
P04406 GAPDH Cytoplasm, Cytoskeleton 4
P68371 β-Tubulin 4B Cytoplasm, Cytoskeleton,
Nucleus
1
P07437 β-Tubulin Cytoplasm, Cytoskeleton. 1
P06733 Alpha-enolase Cytoplasm, Cell membrane 4
O43809 CPSF5 Nucleus 1
P62328 Thymosin β-4 Cytoplasm, Cytoskeleton. 3
P22392 NME2 Cytoplasm, Nucleus 2
Q15942 Zyxin Cytoplasm, Cytoskeleton,
Nucleus, Cell junction
2
P21796 VDAC1 Outer mitochondrial membrane 1
P20962 Parathymosin Nucleus 4
P08559 PDHA1 Mitochondrial matrix 4
P06454 Prothymosin α Nucleus 5
P68871 Hemoglobin β – 1
P02042 Hemoglobin 1 – 1
P09972 ALDOC – 1
P04792 Heat shock protein
beta-1
Cytoplasm, Nucleus 1
P06703 Protein S100-A6 Nucleus envelope, Cell membrane 1
P00338 LDHA A Cytoplasm 4
We specified the subcellular location of proteins and the number of acetylation sites. Lines
filled in blue represent the most relevant variations identified in PD models compared to
control.
Identification of Acetylated Peptides and
Proteins in PD Fibroblasts
To elucidate these differences, PD patients’ data were compared
to Co data. We observed that there were four acetylated
proteins only belonged to Co (Figures 1C–E), however
two of them (Nucleophosmin and Zinc finger protein 784)
were constant. The pairs of thymosin β4 and H2B1B or
H2B1B and H2B1M or Annexin A6 and Histone 1.5 were
additionnally found in Co line when compared to IPD,
GS, and RG lines, respectively. Moreover, Co and PD lines
TABLE 3 | Acetylated proteins in human fibroblasts from control subjects.
Protein ID Protein Name Subecellular Location Ac-K Sites
P07355 Annexin A2 Extracellular space,
Extracellular matrix
10
P04083 Annexin A1 Nucleus, Cytoplasm, Cell
membrane
2
P08670 Vimentin Cytoplasm 4
Q9BQE3 Tubulin α-1C Cytoplasm, Cytoskeleton 2
P08758 Annexin A5 – 3
P21333 Filamin-A Cytoplasm, Cell cortex,
Cytoskeleton.
1
P62805 Histone H4 Nucleus, Chromosome 3
Q9GZZ1 NAA50 Cytoplasm 2
Q09472 HAT p300 Cytoplasm, Nucleus. 1
Q92793 CBP Cytoplasm, Nucleus. 2
Q99880 H2B1L Nucleus, Chromosome 4–7
P04406 GAPDH Cytoplasm, Cytoskeleton 2
P68371 Tubulin β-4B Cytoplasm, Cytoskeleton,
Nucleus
1
P07437 Tubulin β Cytoplasm, Cytoskeleton. 1
P06733 Alpha-enolase Cytoplasm, Cell membrane 4
O43809 CPSF5 Nucleus 1
P62328 Thymosin β-4 Cytoplasm, Cytoskeleton. 2
P22392 NME2 Cytoplasm, Nucleus 2
Q15942 Zyxin Cytoplasm, Cytoskeleton,
Nucleus, Cell junction
2
P21796 VDAC1 Outer mitochondrial
membrane
1
P20962 Parathymosin Nucleus 2
P06454 Prothymosin α Nucleus 4
P68871 Hemoglobin β – 1
P02042 Hemoglobin 1 – 1
P09972 ALDOC – 1
P06703 Protein S100-A6 Nucleus envelope, Cell
membrane
1
P00338 LDHA A Cytoplasm 4
P04075 ALDOA – 1
P08133 ANXA6 Cytoplasm 4
P06748 NPM Cytoplasm, Nucleus 1
Q8NCA9 ZN784 Nucleus 1
P33778 H2B1B Nucleus 3
P16401 Histone1.5 Nucleus 2
The subcellular location of proteins and the number of Ac-k sites.
have acetylated proteins in common. From the detected
acetylated proteins based on the comparison effectuated
respect to Co line, distinct acetylated peptides were identified
and were characteristic of each group. Thus, 2 out of 5
acetylated peptides [STVHEILCK (Annexin A2 protein) and
KGSKKAVTKAQKK (H2B1L protein)] are specific to IPD line,
2 to GS line [FLEQQNKILLAELEQLK (Vimentin protein) and
KGSKKAVTK (H2B1C protein)] and 1 out of 3 to RG line
[GVTQFGNKYIQQTK (CPSF5 protein)]. Of note, proteins
can be acetylated in one or more peptides, and following the
group of healthy subjects or PD patients, the acetylation of
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FIGURE 1 | Acetylated proteins in human fibroblasts. (A) Subcellular location of acetylated proteins (%) in human fibroblasts. (B) Ratio of identified acetylated
peptides/non-acetylated peptides in human fibroblasts, p < 0.03, p < 0.02 and p < 0.01 compared to control (χ2-test). (C–E) Comparison of acetylated proteins and
identified acetylated peptides per proteins between Co line and PD models. (C) Co and IPD lines, (D) Co and GS lines (E) Co and RG lines represent the acetylome of
each group and what they share in common.
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one protein might change from one peptide to another and
be monoactylated, polyacetylated or inexistent. Given that
the fold change of acetylated peptides depend on the relative
abundance of proteins, the level of acetylated peptides was
classified in three categories (Normal, hypoacetylated, and
hyperacetylated). Therefore, it exists more hypoacetylated
peptides in IPD line than in Co line. Also, the percentage
of hyperacetylated peptides was significantly increased
in cells harboring LRRK2 mutations (Figure 2A). By
immunofluorescence staining, we observed that the intensity
of acetylated Histone 4 was significantly reduced in IPD line
(Figures 2B,C).
DISCUSSION
Dysregulation of acetylation machinery can lead to
neurodegenerative diseases. In fact, protein aggregation is a
hallmark of neurodegeneration and it is regulated by protein
acetylation including lysine acetylation (Lee and Finkel, 2009)
and N-terminal acetylation. It has been reported that the
N-terminal acetylation of SNCA prevents its aggregation by
stabilizing protein formation (Bartels et al., 2014), besides
that, N-terminal acetylation can also act as a recognition tag
to mediate protein degradation (Zattas et al., 2013), thus N-
acetylation deficiency could be associated with PD pathogenesis.
Despite this protective effect, N-terminal acetylation can disturb
further proteasome degradation interplaying the N-terminal
ubiquitylation of α-amino group of proteins substrates (Tatham
et al., 2013).
Even though 80% of human proteins are acetylated at their
N-terminal, they are poorly considered (Aksnes et al., 2016). In
this study, the proteins N-terminally acetylated in PD models
are annexin A2, putative annexin A2-like protein, cytosolic
(Thymosin β4, α-enolase), nuclear (parathymosin, protein S100-
A6, prothymosin α), and participate in various cellular processes.
These proteins are more represented in IPD line. In common
to IPD and GS lines, prothymosin α (Qi et al., 2010) and
FIGURE 2 | Modulation of acetylated peptides in human fibroblast (A) Represents in % the fold change of hypoacetylated and hyperacetylated peptides in HFs
compared to Co, *p < 0.05 and **p < 0.01 (χ2-test). (B,C). Acetylated histone 4 (Ac-H4K5K8K12) (red) was detected by immunofluorescence and the nuclei were
stained with Hoechst 33342 (blue), Original magnification: 20X, scale bar corresponds to 10µm. (C) Represents the quantification of fluorescence intensity of labeled
Ac-H4K5K8K12 by imageJ (n = 200 cells). Data represent the mean ± SEM of at least three independent experiments, **p < 0.01 and ***p < 0.001 respect to Co
(Student’s t-test).
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protein S100-A6 (Bartkowska et al., 2017) are, respectively, anti-
apoptotic and stress modulator. α-Enolase is found in RG line
whereas annexin A2 is in all PD models. Annexins (A1, A2,
and A5) are calcium sensors that translocate to plasma or
nuclear membrane (Skrahina et al., 2008) and affect apoptosis
pathways (Debret et al., 2003; Jiang et al., 2015). It remains to
investigate whether the N-acetylated form of these proteins have
a crucial role in the progression of PD. Acetylated thymosin β4
is common to both genetic PD lines, this protein has a critical
role in actin polymerization (Mannherz et al., 2010). Moreover,
LRRK2 mutations influence cytoskeleton organization. In fact,
GTP LRRK2 domain interacts with β-tubulin and increases
the lysine acetylation of α-tubulin. However, this interaction
is altered with G2019S and R1441G LRRK2 mutations and
affects the stability of microtubules (Law et al., 2014). Indeed,
neither microtubule structure nor conformation has affected
by α-tubulin acetylation but influences the tubulin-binding
proteins therefore tubulin functions (Howes et al., 2014).
Damaged mitochondria-induced reactive oxygen species (ROS)
are responsible for α-tubulin hyperacetylation (Bonet-Ponce
et al., 2016). Such modification is required for an adaptive
cell response through autophagy induction, consequently, this
hyperacetylation is negatively regulated by p300 upon stress
(Mackeh et al., 2014). In G2019S LRRK2mutation, the reduction
of mitochondrial membrane potential is accompanied by an
increase of ROS production and an enhancement of the basal
autophagy level (Yakhine-Diop et al., 2014). An impairment of
autophagy induction was also observed in IPD and R1441G
LRRK2 lines (Data not shown). The HATs p300 and CBP
are acetylated in RG line, respectively, at five and 2 lysine
positions, which means p300 basal activity is increased (Drazic
et al., 2016). Even though, HAT and HDAC are involved in
the modulation of protein acetylation, acetyl-CoA availability
is critical. In mammals, acetyl CoA is in part generated from
pyruvate by pyruvate dehydrogenase (PDHA1). Pyruvate is the
final product of glycolysis pathway (Drazic et al., 2016). Some
enzymes of this pathway are lysine acetylated in IPD, GS, and
RG lines. This posttranslational modification can increase or
decrease the enzymatic activity of certain proteins. In the case
of acetylated PDHA1 in RG line, its activity is decreased (Drazic
et al., 2016), therefore the level of acetyl-CoA formation from
glycolysis may be reduced. The different pathways (glycolysis
and fatty acid β-oxidation) generating acetyl CoA interplay
in mitochondria. Generally, mitochondria are defective in PD,
this dysfunction disturbs the acetylation machinery by reducing
HDAC Class III (sirtuins) activity (Schwab et al., 2017).
Additionally, an imbalance between HDAC and HAT activities
lead to hyperacetylation (Park et al., 2016) or hypoacetylation
of proteins. Taken together, proteins are acetylated in IPD
and LRRK2 mutations-associated PD. However, it occurs more
hyperacetylated proteins in cells harboring LRRK2 mutations
than in IPD lines. This variation seems to be associated
with the disease. Moreover, in healthy subjects harboring the
R1441G LRRK2 mutation, the intensity of acetylated proteins
was enhanced (Data not shown). The molecular mechanism of
protein acetylation in PD remains unclear. It will be interesting
to elucidate how proteins can be hypoacetylated in IPD rather
than in Genetic PD.
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